CEL-SCI (NYSE:CVM) Earns Sell Rating from Analysts at StockNews.com

StockNews.com assumed coverage on shares of CEL-SCI (NYSE:CVM) in a research report issued to clients and investors on Saturday. The brokerage set a “sell” rating on the stock.

CEL-SCI Stock Performance

NYSE:CVM opened at $0.39 on Friday. CEL-SCI has a 1-year low of $0.36 and a 1-year high of $3.08. The stock has a market cap of $28.83 million, a P/E ratio of -0.76 and a beta of 0.65. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.31 and a quick ratio of 1.09. The firm has a 50-day moving average of $0.53 and a two-hundred day moving average of $0.86.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the business. Calton & Associates Inc. bought a new stake in CEL-SCI in the third quarter worth approximately $50,000. Plotkin Financial Advisors LLC bought a new position in CEL-SCI during the third quarter valued at about $98,000. Renaissance Technologies LLC boosted its stake in shares of CEL-SCI by 29.9% during the 2nd quarter. Renaissance Technologies LLC now owns 173,800 shares of the company’s stock worth $202,000 after acquiring an additional 40,000 shares in the last quarter. Finally, Geode Capital Management LLC increased its holdings in shares of CEL-SCI by 9.6% during the 3rd quarter. Geode Capital Management LLC now owns 612,861 shares of the company’s stock valued at $650,000 after acquiring an additional 53,879 shares during the last quarter. 12.08% of the stock is owned by institutional investors and hedge funds.

About CEL-SCI

CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company's lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers.